Truist keeps a Buy rating and a $130 price target on ServiceTitan (TTAN). The firm is bullish on the company’s sustained long-term growth and upside prospects across its subscription and platform revenue businesses, expecting a strong Q4 result, the analyst tells investors in a research note. Newer AI investments such as Atlas agentic layer and Maximize Program keep this as one of the firm’s favorite ideas for best-in-class vertical SaaS/fintech growth, Truist adds. Published first on TheFly – the ultima ...

UBS initiated coverage of ALX Oncology (ALXO) with a Buy rating and $6 price target The company has a potential blockbuster program with a CD47 combo currently in Phase II for metastatic breast cancer, the analyst tells investors in a research note. UBS sees ALX reporting a “robust” dataset in mid-2027, demonstrating CD47 inhibitor evorpacept’s efficacy in CD47 high and/or HER2+ metastatic breast cancer patients. Published first on TheFly – the ultimate source for real-time, market-moving breaking financ ...

Truist analyst Peter Osterland keeps a Buy rating and $210 price target on Albemarle (ALB) after the company’s non-deal roadshow. The significant momentum for lithium pricing seen in recent months appears to be sustainable, with strong demand growth particularly driven by the EV and grid storage markets likely to outpace industry supply growth in the near to medium term, the analyst tells investors in a research note. The firm also expects the company’s discipline around costs and capital expenditures to c ...

Truist raised the firm’s price target on AAR Corp. (AIR) to $128 from $107 and keeps a Buy rating on the shares. The company’s recent margin expansion, coupled with strategic repositioning, is recognized in the stock performance but still not accurately reflected in valuation, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on AIR: Dis ...

Allarity (ALLR) Therapeutics closed a $20 million non-convertible debt financing with Streeterville Capital. The transaction is structured as a note purchase agreement pursuant to which the Company issued two non-convertible promissory notes: a promissory note in the original principal amount of $10,930,000 and a secured promissory note in the original principal amount of $10,000,000, together providing approximately $20 million in net proceeds to the Company. The financing is expected to extend the Compan ...

VisionWave (VWAV) Holdings announced that C.M. Composite Materials, together with its wholly owned subsidiary FBM Composite Materials, has entered into a Memorandum of Understanding, MOU, with a large industrial manufacturing group headquartered in India to explore the formation of a joint venture manufacturing platform for advanced aerospace and defense composite components. Under the framework contemplated in the MOU, the parties intend to evaluate the creation of a joint venture manufacturing entity in ...

Needham lowered the firm’s price target on AudioEye (AEYE) to $15 from $25 and keeps a Buy rating on the shares. The company reported a solid Q4, with the best quarter of net new annualized recurring revenue of the year, but the firm is cutting its price target on software multiple compression, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read Mo ...

BofA analyst Alec Stranahan lowered the firm’s price target on Hutchmed (HCM) to $21 from $22 and keeps a Buy rating on the shares. The firm says Hutchmed’s FY25 print “offered some positive steps forward after a weaker 1H25.” Directional commentary about fruquintinib indication expansion in 2026 and increasing the number of Fruzaqla markets bolsters the firm’s confidence that Hutchmed can meet their 2026 guidance for Oncology/Immunology, the analyst tells investors. Published first on TheFly – the ultim ...

Alpha Modus (AMOD)resolved its patent infringement litigation against Brookshire Grocery Co. pending in the United States District Court for the Eastern District of Texas. The litigation involved allegations of infringement relating to Alpha Modus’s patented technologies covering real-time consumer behavior analysis, digital advertising systems, smart retail display technologies, and AI-driven in-store engagement platforms deployed within physical retail environments. All claims between the parties have be ...

B. Riley lowered the firm’s price target on AudioEye (AEYE) to $15.50 from $19 and keeps a Buy rating on the shares. AudioEye reported Q4 results in line with prior expectations, but shares fell 11% in after-hours trading due to lighter FY26 revenue guidance, now implying +9% year over year growth versus consensus of +11%, the analyst tells investors in a research note. Despite this, the company anticipates strong operating leverage with at least 30% y/y adjusted EBITDA growth, accelerating annual recurrin ...